Trial Profile

Didanosine/hydroxycarbamide in patients with HIV-1 infections

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Didanosine/hydroxycarbamide (Primary)
Indications HIV-1 infections
Focus Pharmacodynamics; Therapeutic Use
Sponsors Virostatics

Most Recent Events

02 Mar 2011 Substudy results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
20 Jul 2010 Status changed from recruiting to completed.
19 Jul 2010 Results presented at the the 18th International AIDS Conference (IAC-2010) in July 2010, according to a ViroStatics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com